This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Gliptins

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • in response to a meal, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are released (these hormones are termed incretin hormones)
    • these incretin hormones stimulate insulin and suppress glucagon release (both in a glucose-dependent manner), delay gastric emptying, and increase satiety
    • incretins are rapidly degraded by dipeptidyl peptidase-4 (DPP-4)

  • DPP-4 inhibitors are a class of oral antihyperglycemic agents that work via slowing incretin degradation
    • DPP-4 inhibitors enhance meal-stimulated active GLP-1 and GIP levels by two- to threefold
    • DPP-4 inhibitors reduce the enzymatic degradation of the incretin hormones, GLP-1, and glucose-dependent insulinotropic polypeptide by reducing the activity of serum DPP-4 by >=80% (1)
      • leads to an increased availability of endogenous incretins, stimulating insulin secretion from pancreatic beta-cells and inhibiting glucagon release from pancreatic alpha-cells in a glucose-dependent manner

  • there are currently five gliptins available in the UK:
    • alogliptin
    • linagliptin
    • saxagliptin
    • sitagliptin
    • vildagliptin

  • glycaemic control
    • in a meta-analysis, DPP-4 inhibitors were associated with mean changes from baseline in HbA1c of -0.6% to -1.1% (without adjustment for background therapies, blinding, or placebo comparators) (2)

  • changes in body weight associated with gliptin therapy
    • these agents are regarded as weight neutral with respect to changes of body weight (3)

  • if a gliptin is in combination with sulfonylurea, a lower dose of the sulfonylurea may be needed to reduce the risk of hypoglycaemia

  • in people with renal impairment
    • because most DPP-4 inhibitors are eliminated from the body by renal pathways, dose adjustment is required for patients with moderate or severe renal impairment when treated with alogliptin, sitagliptin, saxagliptin, or vildagliptin
    • linagliptin is primarily cleared by nonrenal mechanisms and therefore does not require dosage adjustment in patients with renal impairment (4)

  • summary of adverse effects associated with gliptin therapy
    • generally have a good safety profile and are well tolerated, with a low risk of hypoglycemia (except when used in combination with insulin or insulin secretagogues)
    • gastrointestinal disturbances are common
    • nasopharyngitis may occur
    • serious hypersensitivity reactions, including anaphylaxis, angioedema, and exfoliative skin reactions, have been reported
    • musculoskeletal and connective tissue disorders (including back pain, arthralgia, myalgia, and arthropathy) may occur
    • there have been reports of acute pancreatitis in patients treated with DPP-4 inhibitors
      • prompt discontinuation of DPP-4 inhibitor treatment is recommended if pancreatitis is suspected (4)

For detailed and up to date information then consult the respective Summary of Product Characteristics (SPC) before prescribing a gliptin.

Reference:

  1. Drucker DJ, Nauck Ma. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006 Nov 11;368(9548):1696-705.
  2. Aroda, V.R., Henry, R.R., Han, J. et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther. 2012; 34: 1247-1258.e1222
  3. Scheen, A.J. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf. 2015; 14: 505-524
  4. Thrasher J. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.Am J Cardiol. 2017 Jul 1;120(1S):S4-S16

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.